JMT101

DRUG9 trials

Sponsors

Shanghai JMT-Bio Inc., Peking University, CSPC Megalith Biopharmaceutical Co.,Ltd.

Conditions

Advanced Solid TumorEGFR Exon20 Insertion MutationsEsophageal Squamous CarcinomaHarboring EGFR Sensitive Mutations NSCLCHead and Neck Squamous Cell CarcinomaLocally Advanced or Metastatic Non-Small Cell Lung CancerLocally Advanced or Metastatic Non-squamous NSCLCMetastatic Colorectal Cancer (mCRC)

Phase 1

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Shanghai JMT-Bio Inc.Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Start: 2020-06-29End: 2022-06-30Target: 48Updated: 2020-12-28

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Shanghai JMT-Bio Inc.Advanced Solid Tumor

Start: 2017-04-11End: 2022-06-30Target: 259Updated: 2020-12-30

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Peking UniversityEsophageal Squamous Carcinoma

Start: 2021-12-25End: 2023-10-31Target: 50Updated: 2021-12-21

Phase 2

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Shanghai JMT-Bio Inc.EGFR Exon20 Insertion Mutations, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Start: 2021-11-20End: 2024-09-30Target: 155Updated: 2021-11-24

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Shanghai JMT-Bio Inc.Metastatic Colorectal Cancer (mCRC)

Start: 2024-01-31End: 2024-12-31Target: 102Updated: 2023-10-18

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Not yet recruitingNCT06319313

Shanghai JMT-Bio Inc.Squamous Cell Non-small Cell Lung Cancer

Start: 2024-05-01End: 2027-12-01Target: 534Updated: 2024-03-20

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not yet recruitingNCT06989671

CSPC Megalith Biopharmaceutical Co.,Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2025-08-30End: 2028-07-30Target: 430Updated: 2025-08-27

Phase 3

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

RecruitingNCT06735391

Shanghai JMT-Bio Inc.Harboring EGFR Sensitive Mutations NSCLC, Locally Advanced or Metastatic Non-squamous NSCLC, Previously Untreated Systematically NSCLC

Start: 2024-10-23End: 2029-05-30Target: 516Updated: 2024-12-16

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Not yet recruitingNCT07134205

Shanghai JMT-Bio Inc.Metastatic Colorectal Cancer (mCRC)

Start: 2025-10-01End: 2028-10-01Target: 252Updated: 2025-08-21

Related Papers

JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.

Journal of Clinical Oncology2025-06-04

A phase II, randomized study of JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC).

Journal of Clinical Oncology2025-01-27

137MO Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study)

ESMO Open2024-03-013 citations

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

Nature Communications2023-06-1212 citations